President Trump Unveils Deals to Lower US Weight-Loss Drug Costs
US President President Trump has revealed agreements designed to lower the expense of in-demand obesity drugs, as drug prices emerge as a priority in his administration's messaging about accessibility.
Key Arrangements with Pharmaceutical Firms
Addressing the public together with pharmaceutical executives at the White House, the President revealed arrangements with Eli Lilly and the drug manufacturer. Consumers are set to pay between $245 and $350 each month for weight-loss drugs such as Wegovy and Zepbound.
Numerous GLP-1 treatments, used to treat type 2 diabetes and excess weight, are priced at exceeding $1,000 monthly lacking insurance or savings.
Expanded Access to Government Health Programs
The deals will increase the company's and Novo Nordisk's access to Medicare and Medicaid, the federal healthcare programs for older and low-income Americans.
The pharmaceutical firm furthermore said in a statement it would be exempt from tariffs for 36 months as part of the arrangement with the Trump administration.
Cost Breakdown
Approximately one in ten of federal health program beneficiaries will be eligible for expanded access to glucagon-like peptide-1 treatments, and will only pay $50, as stated by high-ranking federal officials.
Those covered by the state-federal health plan will see a staggered beginning contingent upon when states opt in to join.
Government-Run Portal Introduction
The weight-loss drugs will be offered at discounted prices on the patient-facing TrumpRx, a government-run portal scheduled to launch by January.
On TrumpRx, Wegovy and Eli Lilly's medication will begin at $350 monthly typically, and decrease to $250 within two years. The Medicare prices of Novo Nordisk's diabetes drug, Wegovy, Mounjaro, and Zepbound will be $245.
Further Drug Choices
Along with Novo Nordisk's Wegovy, Eli Lilly's obesity pill, orforglipron, will be available for $149 for the starting dosage, the manufacturer announced in a statement. The firm's weight-loss medication will be priced at $299 for a beginner dosage.
Those costs are dependent on Food and Drug Administration authorization of the drugs.
Coverage Limitations
GLP-1 medications are often not covered by commercial insurers. National statute forbids the federal program from covering the treatments when employed in obesity treatment, while they often are included when employed against diabetes and circulatory issues. Only a dozen US states offer reimbursement under Medicaid for obesity reasons.
Health Secretary's Comments
Health Secretary Robert F Kennedy Jr, addressing reporters at the executive mansion, declared the agreements were outcomes of several months of talks with the pharmaceutical company and the drug manufacturer. He called overweight "the number one driver of chronic disease" in the US.
"It will be a life-saving measure to patients," the Health Secretary remarked.
"This is not a cure-all, it's not a silver bullet," he noted, stressing the importance of eating habit modifications and fitness routines.
Context of Pharmaceutical Cost Efforts
Starting in summer, the President has been urging pharmaceutical firms to reduce drug prices. He dispatched letters to 17 drug companies in the summer, allowing them a 60-day period to reply to his demands for more affordable prices.
Pfizer was the primary significant drug maker to finalize a agreement with Trump, slashing prices for some medicines by as much as 85% on the government website. The company also agreed to reduce medication prices for the state-federal health plan.
AstraZeneca and the German company have also reached agreements with the federal leadership in the past few weeks.
